Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Price
Data
About
REGN stock price forecast
News
Competitors
Tokenization
Crypto
FAQ
Regeneron Pharmaceuticals, Inc. stock logo

Regeneron Pharmaceuticals, Inc.

REGN·NASDAQ

Last updated as of 2026-02-11 19:13 EST. Stock price information is sourced from TradingView and reflects real-time market prices.

Insights
Calculator
News

REGN stock price change

On the last trading day, REGN stock closed at 760.76 USD, with a price change of 0.77% for the day.
Trade stock futures

About Bitget

The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more

REGN key data

Previous close760.76 USD
Market cap80.41B USD
Volume164.02K
P/E ratio18.30
Dividend yield (TTM)0.47%
Dividend amount0.88 USD
Last ex-dividend dateNov 20, 2025
Last payment dateDec 05, 2025
EPS diluted (TTM)41.56 USD
Net income (FY)4.50B USD
Revenue (FY)14.34B USD
Next report dateApr 30, 2026
EPS estimate9.160 USD
Revenue estimate3.45B USD USD
Shares float101.75M
Beta (1Y)0.72
Tokenized stocks

Have you heard of tokenized stocks?

A new way to trade stocks — anytime, anywhere, 24/7.

Learn more

Regeneron Pharmaceuticals, Inc. overview

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Sector
Health technology
Industry
Pharmaceuticals: Major
CEO
Leonard S. Schleifer
Headquarters
Tarrytown
Website
regeneron.com
Founded
1988
Employees (FY)
15.41K
Change (1Y)
+304 +2.01%
Revenue / Employee (1Y)
930.75K USD
Net income / Employee (1Y)
292.34K USD

REGN Pulse

Daily updates on REGN stock prices, fund flows, and market news, generated by AI and reviewed by our team of analysts. Always DYOR.

• REGN Stock Price 24h change: -3.25%. From 780.28 USD to 754.91 USD. The decline followed a period of post-earnings momentum, with investors taking profits despite positive Phase 3 data for new allergy treatments.
• From a technical perspective, REGN presents a "short-term neutral, long-term bullish" outlook. The stock is currently trading below its 20-day and 50-day moving averages (SMA20: 758.15, SMA50: 758.71) but remains above its 200-day moving average (SMA200: 661.69). Relative Strength Index (RSI) is neutral at 59.49, while the MACD (3.68) suggests a slowing of upward momentum. Key support levels are identified at 753.70 and 733.03.
• Regeneron unveiled Phase 3 data for novel allergen-blocking antibody treatments for cat and birch allergies on February 10, demonstrating significant reduction in symptoms and potentially shifting the treatment paradigm.
• Major investment firms recently adjusted price targets: Bernstein raised its target to $925 citing solid Q4 performance, while Bank of America upgraded the stock to "Buy" with a $860 target due to Eylea HD growth.
• Regeneron increased its quarterly dividend to $0.94 per share (payable March 5), marking a rise from the previous $0.88, reflecting confidence in its cash flow and blockbuster drug portfolio (Dupixent and Eylea HD).
• Fujifilm announced the opening of a $500 million biologics facility in the UK on February 11, highlighting ongoing massive infrastructure investment in the biotechnology manufacturing sector.
• NIST allocated $3.19 million on February 10 to small businesses advancing biotechnology and AI, specifically targeting innovations in biopharmaceutical manufacturing and contactless monitoring of cell cultures.
See more
about 8h ago
• REGN Stock Price 24h change: +2.46%. From 766.63 USD to 785.51 USD.
• From a technical perspective, the stock is in a "short-term bullish recovery": it has successfully reclaimed its 50-day and 200-day moving averages (approx. $758 and $623), signaling strong momentum. However, an RSI near 60 and a high Stochastic value suggest it is approaching overbought territory, potentially leading to short-term consolidation near the $793 resistance level.
• Regeneron announced 36 abstracts for the AAAAI 2026 meeting, featuring first-time Phase 3 data for "first-in-class" antibody treatments for cat and birch allergies, potentially shifting the treatment paradigm.
• Guggenheim raised its REGN price target to $975 from $865, citing robust 26% growth in Dupixent sales and upcoming catalysts like the Eylea HD pre-filled syringe approval expected in Q2 2026.
• The FDA launched a new "PreCheck" pilot program to accelerate the construction and regulatory review of domestic drug manufacturing facilities, prioritizing plants for critical medications to strengthen the U.S. supply chain.
• A surge in biotech M&A activity and IPOs, including Eikon Therapeutics' $381M offering, signals a sector-wide resurgence, though analysts warn of continued regulatory scrutiny over drug pricing.
See more
about 1D ago

REGN stock price forecast

According to technical indicators for REGN stock, the price is likely to fluctuate within the range of 810.67–1009.11 USD over the next week. Market analysts predict that the price of REGN stock will likely fluctuate within the range of 787.32–1028.23 USD over the next months.

Based on 1-year price forecasts from 69 analysts, the highest estimate is 1704.49 USD, while the lowest estimate is 684.37 USD.

For more information, please see the REGN stock price forecast Stock Price Forecast page.

Latest REGN stock news

With just a Bitget account, you can trade stocks and cryptocurrencies at the same time.

Join now!

FAQ

What is the stock price of Regeneron Pharmaceuticals, Inc.?

REGN is currently priced at 760.76 USD — its price has changed by 0.77% over the past 24 hours. You can track the stock price performance of Regeneron Pharmaceuticals, Inc. more closely on the price chart at the top of this page.

What is the stock ticker of Regeneron Pharmaceuticals, Inc.?

Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ, Regeneron Pharmaceuticals, Inc. is traded under the ticker REGN.

What is the stock forecast of REGN?

We've gathered analysts' opinions on Regeneron Pharmaceuticals, Inc.'s future price. According to their forecasts, REGN has a maximum estimate of 7607.60 USD and a minimum estimate of 1521.52 USD.

What is the market cap of Regeneron Pharmaceuticals, Inc.?

Regeneron Pharmaceuticals, Inc. has a market capitalization of 80.41B USD.

What is P/E ratio (TTM)?

The P/E ratio (TTM) stands for price-to-earnings ratio (trailing twelve months). It is a historical valuation metric calculated using a company's earnings per share (EPS) over the most recent twelve consecutive months, reflecting the company's past profitability.

The P/E ratio measures the relationship between a stock's price and a company's profitability, and is often used as a basis for judging whether a stock is "cheap" or "expensive."

P/E ratio = market price (P) ÷ earnings per share (EPS), or P/E ratio = total market capitalization ÷ net profit attributable to shareholders

The interpretation of the P/E ratio (TTM) should always be considered alongside other factors and is mainly used for valuation comparisons rather than as a standalone indicator.

  • A lower P/E ratio (TTM) means investors are paying less for each unit of earnings. This may indicate that the stock is undervalued, or that the market has limited expectations for the company's future growth, such as in mature or slow-growing industries.
  • A higher P/E ratio (TTM) means investors are paying more for each unit of earnings. This often reflects expectations of strong future earnings growth, which is common among growth or technology stocks, though it may also suggest the stock is overvalued.
  • Comparison with peers: Compare the company's P/E (TTM) with the average or median P/E of other companies in the same industry. A significantly higher P/E may require further analysis to determine whether the company's high valuation is justified by stronger growth prospects or competitive advantages.
  • Comparison with historical levels: Compare the company's current P/E (TTM) with its own historical average (such as over the past 5 or 10 years) to assess whether the current valuation is at a historical high or low.
  • Comparison with the broader market: Compare the company's P/E (TTM) with major market indices (such as the S&P 500) to see how the market is valuing the company overall.

P/E ratios can vary widely across industries, and there is no single "ideal" P/E level. A reasonable P/E range depends on the industry, the company's growth potential, and the broader macroeconomic environment. Investment decisions should not rely solely on the P/E ratio (TTM) but should be based on a comprehensive analysis that includes company quality, growth prospects, and financial health.

Can I trade stocks on Bitget?

You can trade stocks on Bitget, but mainly through stock tokens and stock perps, rather than by directly buying or selling traditional stocks.

This approach reflects Bitget's vision as a Universal Exchange (UEX), designed to connect traditional financial markets with cryptocurrency markets.

Bitget currently offers the following stock-related trading formats:

1. Stock tokens (spot)

Nature: Stock tokens are digital tokens pegged to the price of specific traditional stocks (such as TSLAUSDT and NVDAUSDT) and are traded on Bitget's spot market.

Features: When you trade stock tokens, you are buying and holding tokens rather than owning the underlying traditional stocks.

  • The price of these tokens generally follows the price movements of the stocks they are pegged to, such as Tesla or Nvidia.
  • The advantage is that you can participate in the price movements of traditional financial assets, such as U.S. stocks, using cryptocurrencies (for example, USDT), without the need for a traditional brokerage account.

2. Stock perps

Nature: Bitget also offers USDT-margined perpetual futures, commonly referred to as stock perps, based on major U.S. blue-chip stocks such as Tesla and Meta.

Characteristics: Stock perps are derivative products that allow you to take a bullish or bearish view on the future price of an underlying stock through margin trading. These products typically support leverage, such as up to 25x.

It does not involve owning the underlying stock. Instead, profits and losses are settled based on price movements of the futures.

Important note: When trading stock perps on Bitget, you are participating in derivative markets within the cryptocurrency ecosystem. This is fundamentally different from purchasing publicly traded shares through a traditional brokerage, as you do not own equity in the underlying company.

Futures trading and the use of leverage involve high risk. Please ensure you fully understand the risks before trading.

If you wish to directly hold equity in traditional stocks and enjoy shareholder rights (such as receiving dividends), you must trade through a regulated traditional securities brokerage or brokerage platform.

What are the advantages of Bitget's stock perps?

Bitget's stock perps—typically perpetual futures based on stock tokens prices—are an innovative offering that allows cryptocurrency platforms to provide exposure to traditional financial markets.

Compared to traditional stock or futures trading, they offer several unique advantages, primarily due to the platform's trading infrastructure.

Bitget's stock perps, typically USDT-denominated derivatives, offer the following key advantages:

1. Trading convenience and global accessibility

  • 24/7 trading: Traditional stock markets, such as U.S. equity markets, operate during fixed trading hours. In contrast, cryptocurrency derivatives markets are typically open 24/7. This means investors can trade anytime, capitalizing on breaking news or market fluctuations.
  • Lower entry barriers and faster onboarding: Compared with traditional brokerages, which often require extensive identity verification and lengthy account setup processes, Bitget generally offers faster account onboarding. Users can trade using cryptocurrencies such as USDT, without the need for complex fiat deposit and withdrawal procedures.
  • Global accessibility: Users can access derivatives trading linked to globally recognized stocks via the Bitget platform, subject to applicable regulations.

2. Capital efficiency and high leverage

  • High leverage options: Stock perps typically offer higher leverage than traditional stock trading (for example, up to 25x). This allows traders to control larger positions with smaller margin requirements, improving capital efficiency.
    Note: While high leverage can amplify gains, it also amplifies losses proportionally.
  • Two-way trading: Traders can easily take both long and short positions. This means traders can potentially profit from market volatility whether stock prices rise or fall, provided the market direction is correctly anticipated.

3. Trading and settlement using cryptocurrency

  • USDT margin: Stock perps on Bitget typically use USDT (or other stablecoins) as the margin and settlement currency. For users who already hold cryptocurrency, there is no need to convert assets into fiat currency, allowing them to trade directly with stablecoins.
  • Efficient fund transfers: Crypto-based transfers and settlements are typically faster than traditional fiat systems, enabling more efficient global fund allocation.

4. Integration

One-stop platform: Bitget allows users to trade spot cryptocurrencies, crypto derivatives, and stock perps on a single platform, making it easier to manage different asset types in one place.

Risk warning:

While Bitget's stock perps offer several advantages, it is important to understand the associated risks.

  • High leverage risk: Leveraged trading can result in rapid loss of your entire margin.
  • No equity ownership: When trading stock perps, you do not own the underlying shares. As a result, you are not entitled to dividends or voting rights.
  • Market liquidity risk: Tokenized stock perps may have lower liquidity than their counterparts in traditional stock markets, especially outside regular trading hours.

In summary, Bitget's stock perps offer advantages such as greater trading flexibility, lower entry barriers, and higher capital efficiency.

What are the trading fees for Bitget stock perps?

Trading fees for Bitget stock perps (USDT-margined perpetual futures) mainly include transaction fees and funding rates.

Transaction fees:

Bitget offers limited-time fee promotions for stock perps (especially tokenized stock perps) from time to time to attract traders.

Standard reference rates: Under Bitget's standard futures fee structure, the taker fee is typically around 0.06%, while the maker fee is around 0.02%.

Current promotions for stock perps (important): To promote its stock perps products, Bitget is offering discounted transaction fees during Q4 2025, with taker fees as low as 0.006% and maker fees as low as 0.002%. There is also a limited-time promotion offering zero-fee trading for spot stock tokens.

Recommendation: Since promotional activities are subject to change or end at any time, please visit Bitget's official Fee overview or Announcement Center page for the latest and most accurate rates at the time of trading.

Funding rate:

The funding rate is a key mechanism in perpetual futures (including stock perps) that helps keep the futures price closely aligned with the spot price of the underlying asset. It is not a fee charged by the platform, but a periodic payment exchanged between long and short traders.

Funding rates fluctuate dynamically and are mainly driven by market sentiment and imbalances between long and short positions. Stock perps generally experience lower volatility than cryptocurrencies, so funding rates are often relatively low during stable market conditions. However, during earnings seasons or major positive or negative news events, heavy concentration of long or short positions—such as in high-growth technology stocks like Tesla or Nvidia—can create significant imbalances, causing funding rates to spike in the short term.

Funding payments are typically settled every 8 hours. If you close your position before the funding settlement time, no funding payment will be charged or received.

Funding rates are not fixed. If you hold a position for an extended period, high positive funding rates (for long positions) or high negative funding rates (for short positions) will affect your overall holding costs or potential returns. For this reason, it is important to monitor the funding rate in real time on the trading interface.

NASDAQ/
REGN